Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8944590 | 0.94 | KDM4E (0.45) | KDM4ETDP1ALDH1A1POLBNISCH | |
| SCHEMBL8944853 | 0.88 | SIGMAR1 (0.44) | KDM4ETDP1ALDH1A1POLBNISCH | |
| SCHEMBL8944755 | 0.87 | LMNA (0.40) | NISCH | |
| SCHEMBL8944702 | 0.85 | NISCH (0.42) | NISCHSIGMAR1 | |
| SCHEMBL8944902 | 0.83 | CYP2A13 (0.39) | KDM4EALDH1A1POLBNISCHCYP2A13 | |
| SCHEMBL8944840 | 0.82 | KDM4E (0.43) | KDM4ETDP1ALDH1A1POLBCYP2A13 | |
| SCHEMBL2386441 | 0.81 | KDM4E (0.47) | KDM4ETDP1ALDH1A1POLBNISCH | |
| SCHEMBL8944498 | 0.81 | TAAR1 (0.42) | NISCH | |
| SCHEMBL9036092 | 0.80 | KDM4E (0.45) | KDM4ETDP1ALDH1A1POLBCYP2A13 | |
| SCHEMBL8944813 | 0.79 | NISCH (0.47) | NISCHSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309706-B2 | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-12-18 | — | — | US | claimed |
| EP-0638568-B1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1996-10-09 | — | — | EP | claimed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | claimed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | claimed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | claimed |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | ABBOTT PRODUCTS GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | ABBOTT PRODUCTS GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | ABBOTT PRODUCTS GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2005039639-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039639-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1517688-A2 | MEDICAMENT FOR THE TREATMENT OF DISEASES REQUIRING INHIBITION OR A REDUCTION IN THE ACTIVITY OF PH VALUE-REGULATING BICARBONATE TRANSPORTER PROTEINS | Solvay Pharmaceuticals GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000312-A2 | MEDICAMENT FOR THE TREATMENT OF DISEASES REQUIRING INHIBITION OR A REDUCTION IN THE ACTIVITY OF PH VALUE-REGULATING BICARBONATE TRANSPORTER PROTEINS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
| EP-0638568-B1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1996-10-09 | — | — | EP | disclosed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | disclosed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | KDM4E 3259/4885TDP1 486/4885ALDH1A1 1172/4885 |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | AGTR2, AGTR1, REN | KDM4E 4312/4885TDP1 4171/4885ALDH1A1 3066/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | KDM4E 3259/4885TDP1 486/4885ALDH1A1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.